Jasper Therapeutics Inc
JSPR1.860USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
52.05MMarket Cap
LossP/E TTM
More Details of Jasper Therapeutics Inc Company
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Jasper Therapeutics Inc Info
Ticker SymbolJSPR
Company nameJasper Therapeutics Inc
IPO dateNov 20, 2019
CEOMartell (Ronald A)
Number of employees64
Security typeOrdinary Share
Fiscal year-endNov 20
Address2200 Bridge Pkwy Suite #102
CityREDWOOD CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94065
Phone16505491400
Websitehttps://jaspertx.com/
Ticker SymbolJSPR
IPO dateNov 20, 2019
CEOMartell (Ronald A)
Company Executives of Jasper Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Ronald A. (Ron) Martell
Mr. Ronald A. (Ron) Martell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
74.12K
+123.80%
Mr. Jeetinder Singh (Jeet) Mahal
Mr. Jeetinder Singh (Jeet) Mahal
Chief Operating Officer
Chief Operating Officer
25.37K
+1.44%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Thomas G. (Tom) Wiggans
Mr. Thomas G. (Tom) Wiggans
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
4.73K
-5.40%
Mr. Vishal Kapoor
Mr. Vishal Kapoor
Independent Director
Independent Director
4.38K
--
Dr. Judith Shizuru, M.D., Ph.D.
Dr. Judith Shizuru, M.D., Ph.D.
Director
Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Christian W. Nolet
Mr. Christian W. Nolet
Independent Director
Independent Director
--
--
Mr. Herb Cross
Mr. Herb Cross
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Mr. Kurt von Emster
Mr. Kurt von Emster
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ronald A. (Ron) Martell
Mr. Ronald A. (Ron) Martell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
74.12K
+123.80%
Mr. Jeetinder Singh (Jeet) Mahal
Mr. Jeetinder Singh (Jeet) Mahal
Chief Operating Officer
Chief Operating Officer
25.37K
+1.44%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Thomas G. (Tom) Wiggans
Mr. Thomas G. (Tom) Wiggans
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
4.73K
-5.40%
Mr. Vishal Kapoor
Mr. Vishal Kapoor
Independent Director
Independent Director
4.38K
--
Dr. Judith Shizuru, M.D., Ph.D.
Dr. Judith Shizuru, M.D., Ph.D.
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Velan Capital Investment Management LP
9.54%
Acorn Capital Advisors, LLC
6.38%
Simplify Asset Management Inc
5.85%
Soleus Capital Management, L.P.
5.34%
Kingdon Capital Management, L.L.C.
4.73%
Other
68.15%
Shareholders
Shareholders
Proportion
Velan Capital Investment Management LP
9.54%
Acorn Capital Advisors, LLC
6.38%
Simplify Asset Management Inc
5.85%
Soleus Capital Management, L.P.
5.34%
Kingdon Capital Management, L.L.C.
4.73%
Other
68.15%
Shareholder Types
Shareholders
Proportion
Hedge Fund
27.64%
Investment Advisor
24.70%
Investment Advisor/Hedge Fund
13.71%
Research Firm
4.03%
Venture Capital
3.81%
Individual Investor
1.04%
Family Office
0.17%
Other
24.89%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
197
14.93M
53.52%
-5.91M
2025Q2
200
13.30M
88.50%
-6.79M
2025Q1
208
13.43M
89.40%
-7.30M
2024Q4
197
16.02M
106.64%
-3.08M
2024Q3
183
15.58M
105.01%
-3.10M
2024Q2
159
15.59M
105.21%
-1.23M
2024Q1
125
13.80M
93.49%
+2.29M
2023Q4
104
8.47M
79.62%
-3.17M
2023Q3
105
10.07M
95.42%
-1.18M
2023Q2
146
9.80M
93.27%
-1.97M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Velan Capital Investment Management LP
2.67M
9.57%
+1.23M
+86.10%
Sep 19, 2025
Soleus Capital Management, L.P.
1.49M
5.36%
--
--
Jun 30, 2025
Kingdon Capital Management, L.L.C.
765.00K
2.74%
+80.29K
+11.73%
Jul 03, 2025
Rock Springs Capital Management LP
545.17K
1.95%
--
--
Jun 30, 2025
Abingworth Management Limited
1.07M
3.82%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
624.60K
2.24%
-54.85K
-8.07%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
703.65K
2.52%
+891.00
+0.13%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
2.05%
iShares Micro-Cap ETF
0.01%
Vanguard US Momentum Factor ETF
0%
Tema Oncology ETF
0%
Proshares Ultra Russell 2000
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
View more
Simplify Propel Opportunities ETF
Proportion2.05%
iShares Micro-Cap ETF
Proportion0.01%
Vanguard US Momentum Factor ETF
Proportion0%
Tema Oncology ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Date
Type
Ratio
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
Jan 02, 2024
Merger
10→1
FAQs
Who are the top five shareholders of Jasper Therapeutics Inc?
The top five shareholders of Jasper Therapeutics Inc are:
Velan Capital Investment Management LP holds 2.67M shares, accounting for 9.57% of the total shares.
Soleus Capital Management, L.P. holds 1.49M shares, accounting for 5.36% of the total shares.
Kingdon Capital Management, L.L.C. holds 765.00K shares, accounting for 2.74% of the total shares.
Rock Springs Capital Management LP holds 545.17K shares, accounting for 1.95% of the total shares.
Abingworth Management Limited holds 1.07M shares, accounting for 3.82% of the total shares.
Velan Capital Investment Management LP holds 2.67M shares, accounting for 9.57% of the total shares.
Soleus Capital Management, L.P. holds 1.49M shares, accounting for 5.36% of the total shares.
Kingdon Capital Management, L.L.C. holds 765.00K shares, accounting for 2.74% of the total shares.
Rock Springs Capital Management LP holds 545.17K shares, accounting for 1.95% of the total shares.
Abingworth Management Limited holds 1.07M shares, accounting for 3.82% of the total shares.
What are the top three shareholder types of Jasper Therapeutics Inc?
The top three shareholder types of Jasper Therapeutics Inc are:
Velan Capital Investment Management LP
Acorn Capital Advisors, LLC
Simplify Asset Management Inc
Velan Capital Investment Management LP
Acorn Capital Advisors, LLC
Simplify Asset Management Inc
How many institutions hold shares of Jasper Therapeutics Inc (JSPR)?
As of 2025Q3, 197 institutions hold shares of Jasper Therapeutics Inc, with a combined market value of approximately 14.93M, accounting for 53.52% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -34.98%.
What is the biggest source of revenue for Jasper Therapeutics Inc?
In --, the -- business generated the highest revenue for Jasper Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
